Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Protein that may predict future diabetes risk and death from cancer identified
New research, published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]),…
Improving serious illness communication for patients with advanced cancer
Patients with advanced cancer want and need to partner with their care team to make…
UK men warned about risk of skin cancer as temperature reaches 40 degrees
Skin cancer death rates in UK men have more than tripled since the early 1970s,…
Palbociclib combination in advanced breast cancer: Again only disadvantages
- SABCS 2022: T-DXd yields longer overall survival than T-DM1 in patients with HER2-positive metastatic breast cancer
- SABCS 2022: Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer
- SABCS 2022: Adding capivasertib to fulvestrant improves progression-free survival in patients with advanced hormone receptor-positive breast cancer
The only journey is within: A new exhibition on the cancer journey
Modern medicine that is heavily dependent on technology may at times be perceived as detached from human suffering. Art, on…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.